false2021Q2000071140410/31us-gaap:AccountingStandardsUpdate201613Member00007114042020-11-012021-04-30xbrli:shares00007114042021-05-28iso4217:USD00007114042021-02-012021-04-3000007114042020-02-012020-04-3000007114042019-11-012020-04-30iso4217:USDxbrli:shares00007114042021-04-3000007114042020-10-310000711404coo:CommonStockExcludingTreasuryStockParNetValueMember2019-10-310000711404us-gaap:TreasuryStockMember2019-10-310000711404coo:TreasuryStockParNetValueMember2019-10-310000711404us-gaap:AdditionalPaidInCapitalMember2019-10-310000711404us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-10-310000711404us-gaap:RetainedEarningsMember2019-10-310000711404us-gaap:NoncontrollingInterestMember2019-10-3100007114042019-10-310000711404us-gaap:RetainedEarningsMember2019-11-012020-01-3100007114042019-11-012020-01-310000711404us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-11-012020-01-310000711404coo:CommonStockExcludingTreasuryStockParNetValueMember2019-11-012020-01-310000711404us-gaap:AdditionalPaidInCapitalMember2019-11-012020-01-310000711404coo:CommonStockExcludingTreasuryStockParNetValueMember2020-01-310000711404us-gaap:TreasuryStockMember2020-01-310000711404coo:TreasuryStockParNetValueMember2020-01-310000711404us-gaap:AdditionalPaidInCapitalMember2020-01-310000711404us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-310000711404us-gaap:RetainedEarningsMember2020-01-310000711404us-gaap:NoncontrollingInterestMember2020-01-3100007114042020-01-310000711404us-gaap:RetainedEarningsMember2020-02-012020-04-300000711404us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-02-012020-04-300000711404coo:CommonStockExcludingTreasuryStockParNetValueMember2020-02-012020-04-300000711404us-gaap:AdditionalPaidInCapitalMember2020-02-012020-04-300000711404us-gaap:TreasuryStockMember2020-02-012020-04-300000711404coo:CommonStockExcludingTreasuryStockParNetValueMember2020-04-300000711404us-gaap:TreasuryStockMember2020-04-300000711404coo:TreasuryStockParNetValueMember2020-04-300000711404us-gaap:AdditionalPaidInCapitalMember2020-04-300000711404us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-04-300000711404us-gaap:RetainedEarningsMember2020-04-300000711404us-gaap:NoncontrollingInterestMember2020-04-3000007114042020-04-300000711404coo:CommonStockExcludingTreasuryStockParNetValueMember2020-10-310000711404us-gaap:TreasuryStockMember2020-10-310000711404coo:TreasuryStockParNetValueMember2020-10-310000711404us-gaap:AdditionalPaidInCapitalMember2020-10-310000711404us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-10-310000711404us-gaap:RetainedEarningsMember2020-10-310000711404us-gaap:NoncontrollingInterestMember2020-10-310000711404us-gaap:RetainedEarningsMember2020-11-012021-01-3100007114042020-11-012021-01-310000711404us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-11-012021-01-310000711404coo:CommonStockExcludingTreasuryStockParNetValueMember2020-11-012021-01-310000711404us-gaap:AdditionalPaidInCapitalMember2020-11-012021-01-310000711404us-gaap:TreasuryStockMember2020-11-012021-01-3100007114042019-11-012020-10-310000711404us-gaap:RetainedEarningsMembersrt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2020-10-310000711404srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2020-10-310000711404coo:CommonStockExcludingTreasuryStockParNetValueMember2021-01-310000711404us-gaap:TreasuryStockMember2021-01-310000711404coo:TreasuryStockParNetValueMember2021-01-310000711404us-gaap:AdditionalPaidInCapitalMember2021-01-310000711404us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-310000711404us-gaap:RetainedEarningsMember2021-01-310000711404us-gaap:NoncontrollingInterestMember2021-01-3100007114042021-01-310000711404us-gaap:RetainedEarningsMember2021-02-012021-04-300000711404us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-02-012021-04-300000711404coo:CommonStockExcludingTreasuryStockParNetValueMember2021-02-012021-04-300000711404us-gaap:AdditionalPaidInCapitalMember2021-02-012021-04-300000711404us-gaap:TreasuryStockMember2021-02-012021-04-300000711404coo:CommonStockExcludingTreasuryStockParNetValueMember2021-04-300000711404us-gaap:TreasuryStockMember2021-04-300000711404coo:TreasuryStockParNetValueMember2021-04-300000711404us-gaap:AdditionalPaidInCapitalMember2021-04-300000711404us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-04-300000711404us-gaap:RetainedEarningsMember2021-04-300000711404us-gaap:NoncontrollingInterestMember2021-04-300000711404coo:SeriesOfIndividuallyImmaterialBusinessAcquisitionsAndAssetAcquisitionsMemberus-gaap:TechnologyBasedIntangibleAssetsMember2021-04-300000711404coo:SeriesOfIndividuallyImmaterialBusinessAcquisitionsAndAssetAcquisitionsMemberus-gaap:TechnologyBasedIntangibleAssetsMember2020-10-310000711404coo:SeriesOfIndividuallyImmaterialBusinessAcquisitionsAndAssetAcquisitionsMemberus-gaap:InProcessResearchAndDevelopmentMember2021-04-300000711404coo:SeriesOfIndividuallyImmaterialBusinessAcquisitionsAndAssetAcquisitionsMemberus-gaap:InProcessResearchAndDevelopmentMember2020-10-310000711404coo:SeriesOfIndividuallyImmaterialBusinessAcquisitionsAndAssetAcquisitionsMemberus-gaap:CustomerRelationshipsMember2021-04-300000711404coo:SeriesOfIndividuallyImmaterialBusinessAcquisitionsAndAssetAcquisitionsMemberus-gaap:CustomerRelationshipsMember2020-10-310000711404us-gaap:TrademarksMembercoo:SeriesOfIndividuallyImmaterialBusinessAcquisitionsAndAssetAcquisitionsMember2021-04-300000711404us-gaap:TrademarksMembercoo:SeriesOfIndividuallyImmaterialBusinessAcquisitionsAndAssetAcquisitionsMember2020-10-310000711404coo:SeriesOfIndividuallyImmaterialBusinessAcquisitionsAndAssetAcquisitionsMemberus-gaap:OtherIntangibleAssetsMember2021-04-300000711404coo:SeriesOfIndividuallyImmaterialBusinessAcquisitionsAndAssetAcquisitionsMemberus-gaap:OtherIntangibleAssetsMember2020-10-310000711404coo:SeriesOfIndividuallyImmaterialBusinessAcquisitionsAndAssetAcquisitionsMember2021-04-300000711404coo:SeriesOfIndividuallyImmaterialBusinessAcquisitionsAndAssetAcquisitionsMember2020-10-310000711404coo:PrivatelyHeldMedicalDeviceCompanyDevelopedMaraWaterVaporAblationSystemMember2021-02-010000711404coo:PrivatelyHeldMedicalDeviceCompanyMember2021-01-012021-01-190000711404coo:PrivatelyHeldMedicalDeviceCompanyMember2021-01-192021-01-190000711404coo:PrivatelyHeldMedicalDeviceCompanyPortionAttributableToFormerEquityInterestOwnersMember2021-01-190000711404coo:PrivatelyHeldMedicalDeviceCompanyMember2021-01-190000711404coo:PrivatelyHeldMedicalDeviceCompanyMember2020-11-012021-04-300000711404coo:PrivatelyHeldMedicalDeviceCompanyMember2021-02-012021-04-300000711404coo:CoopervisionSegmentMember2020-10-310000711404coo:CoopersurgicalSegmentMember2020-10-310000711404coo:CoopervisionSegmentMember2020-11-012021-04-300000711404coo:CoopersurgicalSegmentMember2020-11-012021-04-300000711404coo:CoopervisionSegmentMember2021-04-300000711404coo:CoopersurgicalSegmentMember2021-04-3000007114042020-05-012020-07-310000711404coo:CompositeMember2021-04-300000711404coo:CompositeMember2020-10-310000711404coo:CompositeMember2020-11-012021-04-300000711404us-gaap:TechnologyBasedIntangibleAssetsMember2021-04-300000711404us-gaap:TechnologyBasedIntangibleAssetsMember2020-10-310000711404us-gaap:TechnologyBasedIntangibleAssetsMember2020-11-012021-04-300000711404us-gaap:CustomerRelationshipsMember2021-04-300000711404us-gaap:CustomerRelationshipsMember2020-10-310000711404us-gaap:CustomerRelationshipsMember2020-11-012021-04-300000711404us-gaap:TrademarksMember2021-04-300000711404us-gaap:TrademarksMember2020-10-310000711404us-gaap:TrademarksMember2020-11-012021-04-300000711404coo:LicenseAndDistributionRightsAndOtherMember2021-04-300000711404coo:LicenseAndDistributionRightsAndOtherMember2020-10-310000711404coo:LicenseAndDistributionRightsAndOtherMember2020-11-012021-04-300000711404coo:OverdraftAndOtherCreditFacilitiesMember2021-04-300000711404coo:OverdraftAndOtherCreditFacilitiesMember2020-10-310000711404coo:TermLoansMember2021-04-300000711404coo:TermLoansMember2020-10-310000711404us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2021-04-300000711404us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2020-10-310000711404us-gaap:MediumTermNotesMember2021-04-300000711404us-gaap:MediumTermNotesMember2020-10-310000711404coo:OtherDebtMember2021-04-300000711404coo:OtherDebtMember2020-10-310000711404coo:TermLoanAgreement2020Membercoo:TermLoansMember2020-10-162020-10-160000711404coo:TermLoanAgreement2020Membercoo:TermLoansMember2020-10-160000711404coo:TermLoanAgreement2020Membercoo:TermLoansMember2021-04-30xbrli:pure0000711404coo:TermLoanAgreement2020Membercoo:TermLoansMemberus-gaap:BaseRateMember2020-10-162020-10-160000711404coo:TermLoanAgreement2020Membercoo:TermLoansMemberus-gaap:LondonInterbankOfferedRateLIBORMember2020-10-162020-10-160000711404us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMembercoo:CreditAgreement2020Member2020-04-010000711404us-gaap:LineOfCreditMembercoo:CreditAgreement2020Membercoo:TermLoanFacility2020Member2020-04-010000711404coo:RevolvingCreditFacilityAndTermLoanFacility2020Memberus-gaap:LineOfCreditMembercoo:CreditAgreement2020Member2020-04-010000711404coo:RevolvingCreditFacilityAndTermLoanFacility2020Memberus-gaap:LineOfCreditMembersrt:MinimumMembercoo:CreditAgreement2020Memberus-gaap:BaseRateMember2020-04-012020-04-010000711404coo:RevolvingCreditFacilityAndTermLoanFacility2020Membersrt:MaximumMemberus-gaap:LineOfCreditMembercoo:CreditAgreement2020Memberus-gaap:BaseRateMember2020-04-012020-04-010000711404coo:RevolvingCreditFacilityAndTermLoanFacility2020Memberus-gaap:LineOfCreditMembersrt:MinimumMembercoo:CreditAgreement2020Memberus-gaap:LondonInterbankOfferedRateLIBORMember2020-04-012020-04-010000711404coo:RevolvingCreditFacilityAndTermLoanFacility2020Membersrt:MaximumMemberus-gaap:LineOfCreditMembercoo:CreditAgreement2020Memberus-gaap:LondonInterbankOfferedRateLIBORMember2020-04-012020-04-010000711404us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMembercoo:CreditAgreement2020Membersrt:MinimumMember2020-04-012020-04-010000711404srt:MaximumMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMembercoo:CreditAgreement2020Member2020-04-012020-04-010000711404us-gaap:LineOfCreditMembercoo:CreditAgreement2020Membercoo:TermLoanFacility2020Member2020-04-012020-04-010000711404us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMembercoo:CreditAgreement2020Member2020-04-012020-04-010000711404us-gaap:LineOfCreditMembercoo:CreditAgreement2020Membercoo:TermLoanFacility2020Member2021-04-300000711404us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMembercoo:CreditAgreement2020Member2021-04-300000711404us-gaap:LineOfCreditMembercoo:CreditAgreement2020Membercoo:TermLoanFacility2020Member2020-11-012021-04-300000711404us-gaap:LineOfCreditMembercoo:CreditAgreement2020Membercoo:TermLoanFacility2020Member2021-02-012021-04-300000711404coo:RevolvingCreditFacilityAndTermLoanFacility2020Memberus-gaap:LineOfCreditMembercoo:CreditAgreement2020Member2020-04-012020-04-010000711404coo:RevolvingCreditFacilityAndTermLoanFacility2020Memberus-gaap:LineOfCreditMembercoo:CreditAgreement2020Member2021-04-300000711404coo:RevolvingCreditFacilityAndTermLoanFacility2020Memberus-gaap:LineOfCreditMembercoo:CreditAgreement2020Member2020-11-012021-04-300000711404coo:CreditAgreement2020AndTermLoanAgreement2020Member2021-04-300000711404us-gaap:EmployeeStockOptionMember2021-02-012021-04-300000711404us-gaap:EmployeeStockOptionMember2020-02-012020-04-300000711404us-gaap:EmployeeStockOptionMember2020-11-012021-04-300000711404us-gaap:EmployeeStockOptionMember2019-11-012020-04-300000711404us-gaap:RestrictedStockUnitsRSUMember2021-02-012021-04-300000711404us-gaap:RestrictedStockUnitsRSUMember2020-02-012020-04-300000711404us-gaap:RestrictedStockUnitsRSUMember2020-11-012021-04-300000711404us-gaap:RestrictedStockUnitsRSUMember2019-11-012020-04-300000711404us-gaap:SellingGeneralAndAdministrativeExpensesMember2021-02-012021-04-300000711404us-gaap:SellingGeneralAndAdministrativeExpensesMember2020-02-012020-04-300000711404us-gaap:SellingGeneralAndAdministrativeExpensesMember2020-11-012021-04-300000711404us-gaap:SellingGeneralAndAdministrativeExpensesMember2019-11-012020-04-300000711404us-gaap:CostOfSalesMember2021-02-012021-04-300000711404us-gaap:CostOfSalesMember2020-02-012020-04-300000711404us-gaap:CostOfSalesMember2020-11-012021-04-300000711404us-gaap:CostOfSalesMember2019-11-012020-04-300000711404us-gaap:ResearchAndDevelopmentExpenseMember2021-02-012021-04-300000711404us-gaap:ResearchAndDevelopmentExpenseMember2020-02-012020-04-300000711404us-gaap:ResearchAndDevelopmentExpenseMember2020-11-012021-04-300000711404us-gaap:ResearchAndDevelopmentExpenseMember2019-11-012020-04-300000711404us-gaap:AccumulatedTranslationAdjustmentMember2019-10-310000711404us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2019-10-310000711404us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2019-10-310000711404us-gaap:AccumulatedTranslationAdjustmentMember2019-11-012020-10-310000711404us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2019-11-012020-10-310000711404us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2019-11-012020-10-310000711404us-gaap:AccumulatedTranslationAdjustmentMember2020-10-310000711404us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-10-310000711404us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2020-10-310000711404us-gaap:AccumulatedTranslationAdjustmentMember2020-11-012021-04-300000711404us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-11-012021-04-300000711404us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2020-11-012021-04-300000711404us-gaap:AccumulatedTranslationAdjustmentMember2021-04-300000711404us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-04-300000711404us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-04-3000007114042011-12-3100007114042017-03-3100007114042021-02-092021-02-0900007114042020-02-102020-02-10coo:interest_rate_swap_contract0000711404us-gaap:InterestRateSwapMember2020-04-060000711404us-gaap:InterestRateSwapMember2020-04-062020-04-060000711404us-gaap:InterestRateSwapMember2021-04-30coo:segment0000711404us-gaap:OperatingSegmentsMembercoo:CoopervisionSegmentMembercoo:ToricLensMember2021-02-012021-04-300000711404us-gaap:OperatingSegmentsMembercoo:CoopervisionSegmentMembercoo:ToricLensMember2020-02-012020-04-300000711404us-gaap:OperatingSegmentsMembercoo:CoopervisionSegmentMembercoo:ToricLensMember2020-11-012021-04-300000711404us-gaap:OperatingSegmentsMembercoo:CoopervisionSegmentMembercoo:ToricLensMember2019-11-012020-04-300000711404us-gaap:OperatingSegmentsMembercoo:CoopervisionSegmentMembercoo:MultifocalLensMember2021-02-012021-04-300000711404us-gaap:OperatingSegmentsMembercoo:CoopervisionSegmentMembercoo:MultifocalLensMember2020-02-012020-04-300000711404us-gaap:OperatingSegmentsMembercoo:CoopervisionSegmentMembercoo:MultifocalLensMember2020-11-012021-04-300000711404us-gaap:OperatingSegmentsMembercoo:CoopervisionSegmentMembercoo:MultifocalLensMember2019-11-012020-04-300000711404us-gaap:OperatingSegmentsMembercoo:SingleUseSphereLensMembercoo:CoopervisionSegmentMember2021-02-012021-04-300000711404us-gaap:OperatingSegmentsMembercoo:SingleUseSphereLensMembercoo:CoopervisionSegmentMember2020-02-012020-04-300000711404us-gaap:OperatingSegmentsMembercoo:SingleUseSphereLensMembercoo:CoopervisionSegmentMember2020-11-012021-04-300000711404us-gaap:OperatingSegmentsMembercoo:SingleUseSphereLensMembercoo:CoopervisionSegmentMember2019-11-012020-04-300000711404us-gaap:OperatingSegmentsMembercoo:CoopervisionSegmentMembercoo:NonSingleUseSphereAndOtherMember2021-02-012021-04-300000711404us-gaap:OperatingSegmentsMembercoo:CoopervisionSegmentMembercoo:NonSingleUseSphereAndOtherMember2020-02-012020-04-300000711404us-gaap:OperatingSegmentsMembercoo:CoopervisionSegmentMembercoo:NonSingleUseSphereAndOtherMember2020-11-012021-04-300000711404us-gaap:OperatingSegmentsMembercoo:CoopervisionSegmentMembercoo:NonSingleUseSphereAndOtherMember2019-11-012020-04-300000711404us-gaap:OperatingSegmentsMembercoo:CoopervisionSegmentMember2021-02-012021-04-300000711404us-gaap:OperatingSegmentsMembercoo:CoopervisionSegmentMember2020-02-012020-04-300000711404us-gaap:OperatingSegmentsMembercoo:CoopervisionSegmentMember2020-11-012021-04-300000711404us-gaap:OperatingSegmentsMembercoo:CoopervisionSegmentMember2019-11-012020-04-300000711404us-gaap:OperatingSegmentsMembercoo:CoopersurgicalSegmentMembercoo:OfficeAndSurgicalProductsMember2021-02-012021-04-300000711404us-gaap:OperatingSegmentsMembercoo:CoopersurgicalSegmentMembercoo:OfficeAndSurgicalProductsMember2020-02-012020-04-300000711404us-gaap:OperatingSegmentsMembercoo:CoopersurgicalSegmentMembercoo:OfficeAndSurgicalProductsMember2020-11-012021-04-300000711404us-gaap:OperatingSegmentsMembercoo:CoopersurgicalSegmentMembercoo:OfficeAndSurgicalProductsMember2019-11-012020-04-300000711404us-gaap:OperatingSegmentsMembercoo:CoopersurgicalSegmentMembercoo:FertilityMember2021-02-012021-04-300000711404us-gaap:OperatingSegmentsMembercoo:CoopersurgicalSegmentMembercoo:FertilityMember2020-02-012020-04-300000711404us-gaap:OperatingSegmentsMembercoo:CoopersurgicalSegmentMembercoo:FertilityMember2020-11-012021-04-300000711404us-gaap:OperatingSegmentsMembercoo:CoopersurgicalSegmentMembercoo:FertilityMember2019-11-012020-04-300000711404us-gaap:OperatingSegmentsMembercoo:CoopersurgicalSegmentMember2021-02-012021-04-300000711404us-gaap:OperatingSegmentsMembercoo:CoopersurgicalSegmentMember2020-02-012020-04-300000711404us-gaap:OperatingSegmentsMembercoo:CoopersurgicalSegmentMember2020-11-012021-04-300000711404us-gaap:OperatingSegmentsMembercoo:CoopersurgicalSegmentMember2019-11-012020-04-300000711404us-gaap:CorporateNonSegmentMember2021-02-012021-04-300000711404us-gaap:CorporateNonSegmentMember2020-02-012020-04-300000711404us-gaap:CorporateNonSegmentMember2020-11-012021-04-300000711404us-gaap:CorporateNonSegmentMember2019-11-012020-04-300000711404us-gaap:OperatingSegmentsMembercoo:CoopervisionSegmentMember2021-04-300000711404us-gaap:OperatingSegmentsMembercoo:CoopervisionSegmentMember2020-10-310000711404us-gaap:OperatingSegmentsMembercoo:CoopersurgicalSegmentMember2021-04-300000711404us-gaap:OperatingSegmentsMembercoo:CoopersurgicalSegmentMember2020-10-310000711404us-gaap:CorporateNonSegmentMember2021-04-300000711404us-gaap:CorporateNonSegmentMember2020-10-310000711404country:US2021-02-012021-04-300000711404country:US2020-02-012020-04-300000711404country:US2020-11-012021-04-300000711404country:US2019-11-012020-04-300000711404srt:EuropeMember2021-02-012021-04-300000711404srt:EuropeMember2020-02-012020-04-300000711404srt:EuropeMember2020-11-012021-04-300000711404srt:EuropeMember2019-11-012020-04-300000711404coo:RestOfWorldExcludingUnitedStatesAndEuropeMember2021-02-012021-04-300000711404coo:RestOfWorldExcludingUnitedStatesAndEuropeMember2020-02-012020-04-300000711404coo:RestOfWorldExcludingUnitedStatesAndEuropeMember2020-11-012021-04-300000711404coo:RestOfWorldExcludingUnitedStatesAndEuropeMember2019-11-012020-04-300000711404country:US2021-04-300000711404country:US2020-10-310000711404srt:EuropeMember2021-04-300000711404srt:EuropeMember2020-10-310000711404coo:RestOfWorldExcludingUnitedStatesAndEuropeMember2021-04-300000711404coo:RestOfWorldExcludingUnitedStatesAndEuropeMember2020-10-310000711404us-gaap:InterestRateSwapMember2020-10-310000711404us-gaap:InterestRateSwapMember2020-11-012021-04-300000711404us-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherCurrentAssetsMember2021-04-300000711404us-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherCurrentAssetsMember2020-04-300000711404us-gaap:InterestRateSwapMemberus-gaap:OtherNoncurrentAssetsMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-04-300000711404us-gaap:InterestRateSwapMemberus-gaap:OtherNoncurrentAssetsMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-04-300000711404us-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-04-300000711404us-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-04-300000711404us-gaap:InterestRateSwapMemberus-gaap:OtherCurrentLiabilitiesMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-04-300000711404us-gaap:InterestRateSwapMemberus-gaap:OtherCurrentLiabilitiesMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-04-300000711404us-gaap:InterestRateSwapMemberus-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-04-300000711404us-gaap:InterestRateSwapMemberus-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-04-300000711404us-gaap:InterestRateSwapMemberus-gaap:InterestExpenseMember2021-02-012021-04-300000711404us-gaap:InterestRateSwapMemberus-gaap:InterestExpenseMember2020-02-012020-04-300000711404us-gaap:InterestRateSwapMemberus-gaap:InterestExpenseMember2020-11-012021-04-300000711404us-gaap:InterestRateSwapMemberus-gaap:InterestExpenseMember2019-11-012020-04-300000711404coo:AccumulatedGainLossNetCashFlowHedgeBeforeTaxParentMember2020-10-310000711404coo:AccumulatedGainLossNetCashFlowHedgeBeforeTaxParentMember2021-04-30

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_____________________________________________________________
FORM 10-Q
_____________________________________________________________
Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
For the quarterly period ended April 30, 2021
Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
For the transition period from              to             
Commission File Number 1-8597
_____________________________________________________________
The Cooper Companies, Inc.
(Exact name of registrant as specified in its charter)
_____________________________________________________________
Delaware 94-2657368
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer
Identification No.)
6101 Bollinger Canyon Road, Suite 500,
San Ramon, California 94583
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code (925) 460-3600
_____________________________________________________________
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol Name of each exchange on which registered
Common Stock, $.10 par value COO The New York Stock Exchange
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes      No  
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes      No  
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer Accelerated filer
Non-accelerated filer
Smaller reporting company
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act.):    Yes      No  
On May 28, 2021, 49,247,946 shares of Common Stock, $0.10 par value, were outstanding.



INDEX
 
    Page No.
PART I.
Item 1.
3
4
5
7
8
Item 2.
Item 3.
Item 4.
PART II.
Item 1.
Item 1A.
Item 2.
Item 3.
Item 4.
Item 5.
Item 6.
2

PART I. FINANCIAL INFORMATION
Item 1. Unaudited Financial Statements
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
Consolidated Statements of Income and Comprehensive Income (Loss)
Periods Ended April 30,
(In millions, except for earnings per share)
(Unaudited)
Three Months Six Months
  
2021 2020 2021 2020
Net sales $ 719.5  $ 524.9  $ 1,400.0  $ 1,171.1 
Cost of sales 232.4  201.4  462.2  421.1 
Gross profit 487.1  323.5  937.8  750.0 
Selling, general and administrative expense 285.8  237.2  547.0  495.5 
Research and development expense 21.0  23.8  42.4  46.0 
Amortization of intangibles 37.1  33.9  71.8  68.8 
Operating income 143.2  28.6  276.6  139.7 
Interest expense 6.1  12.8  12.5  24.4 
Other expense (income), net 0.7  6.8  (11.8) 8.9 
Income before income taxes 136.4  9.0  275.9  106.4 
Provision for income taxes (Note 6) 18.9  (2.5) (1,942.7) 4.4 
Net income $ 117.5  $ 11.5  $ 2,218.6  $ 102.0 
Earnings per share (Note 7):
Basic $ 2.39  $ 0.23  $ 45.12  $ 2.07 
Diluted $ 2.36  $ 0.23  $ 44.65  $ 2.05 
Number of shares used to compute earnings per share:
Basic 49.2  49.2  49.2  49.2 
Diluted 49.7  49.6  49.7  49.7 
Other comprehensive income (loss), net of tax:
Cash flow hedges $ 15.2  (13.5) $ 19.7  (13.5)
Foreign currency translation adjustment 18.9  (68.9) 105.1  (52.2)
Comprehensive income (loss) $ 151.6  $ (70.9) $ 2,343.4  $ 36.3 

The accompanying notes are an integral part of these Consolidated Condensed Financial Statements.

3


THE COOPER COMPANIES, INC. AND SUBSIDIARIES

Consolidated Condensed Balance Sheets
(In millions, unaudited)
April 30, 2021 October 31, 2020
ASSETS
Current assets:
Cash and cash equivalents $ 105.9  $ 115.9 
Trade accounts receivable, net of allowance for credit losses of $10.7 at April 30, 2021 and $10.2 at October 31, 2020
490.1  435.4 
Inventories (Note 3) 582.0  570.4 
Prepaid expense and other current assets 144.6  152.5 
Total current assets 1,322.6  1,274.2 
Property, plant and equipment, at cost 2,581.4  2,474.8 
Less: accumulated depreciation and amortization 1,271.4  1,192.9 
1,310.0  1,281.9 
Operating lease right-of-use assets 264.9  260.2 
Goodwill (Note 4) 2,567.7  2,447.3 
Other intangibles, net (Note 4) 1,412.4  1,289.0 
Deferred tax assets (Note 6) 2,017.4  80.1 
Other assets 118.8  104.8 
Total assets $ 9,013.8  $ 6,737.5 
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Short-term debt (Note 5) $ 412.6  $ 409.3 
Accounts payable 141.6  176.0 
Employee compensation and benefits 127.0  119.0 
Operating lease liabilities 34.2  33.3 
Other current liabilities 277.3  266.8 
Total current liabilities 992.7  1,004.4 
Long-term debt (Note 5) 1,324.9  1,383.9 
Deferred tax liabilities (Note 6) 22.3  25.8 
Long-term tax payable (Note 6) 149.5  162.0 
Operating lease liabilities 240.9  236.8 
Accrued pension liability and other 120.7  99.8 
Total liabilities $ 2,851.0  $ 2,912.7 
Contingencies (Note 12)
Stockholders’ equity (Note 9):
Preferred stock, 10 cents par value, 1.0 shares authorized, zero shares issued or outstanding
—  — 
Common stock, 10 cents par value, 120.0 shares authorized, 53.6 issued and 49.2 outstanding at April 30, 2021 and 53.4 issued and 49.1 outstanding at October 31, 2020
5.4  5.3 
Additional paid-in capital 1,667.8  1,646.8 
Accumulated other comprehensive loss (347.2) (472.0)
Retained earnings 5,477.5  3,261.8 
Treasury stock at cost: 4.4 shares at April 30, 2021 and 4.3 shares at October 31, 2020
(640.9) (617.3)
Total Cooper stockholders’ equity 6,162.6  3,824.6 
Noncontrolling interests 0.2  0.2 
Stockholders’ equity 6,162.8  3,824.8 
Total liabilities and stockholders’ equity $ 9,013.8  $ 6,737.5 
    
The accompanying notes are an integral part of these Consolidated Condensed Financial Statements.
4


THE COOPER COMPANIES, INC. AND SUBSIDIARIES

Consolidated Condensed Statements of Stockholders' Equity
(In millions, unaudited)
  Common Shares Treasury Stock Additional Paid-In Capital Accumulated
Other
Comprehensive
Income (Loss)
Retained Earnings Treasury Stock Noncontrolling Interests Total
Stockholders'
Equity
Shares Amount Shares Amount
Balance at November 1, 2019 49.1  $ 4.9  4.1  $ 0.4  $ 1,615.0  $ (447.1) $ 3,026.4  $ (571.2) $ 0.2  $ 3,628.6 
Net income attributable to Cooper stockholders —  —  —  —  —  —  90.5  —  —  90.5 
Other comprehensive income, net of tax —  —  —  —  —  16.7  —  —  —  16.7 
Issuance of common stock for stock plans, net 0.1  —  —  —  (13.2) —  —  —  —  (13.1)
Dividends on common stock ($0.03 per share)
—  —  —  —  —  —  (1.5) —  —  (1.5)
Share-based compensation expense —  —  —  —  9.7  —  —  —  —  9.7 
Balance at January 31, 2020 49.2  $ 4.9  4.1  $ 0.4  $ 1,611.6  $ (430.4) $ 3,115.4  $ (571.2) $ 0.2  $ 3,730.9 
Net income attributable to Cooper stockholders —  —  —  —  —  —  11.5  —  —  11.5 
Other comprehensive loss, net of tax —  —  —  —  —  (82.4) —  —  —  (82.4)
Issuance of common stock for stock plans, net 0.1  —  —  —  5.0  —  —  —  —  5.0 
Issuance of common stock for employee stock purchase plan —  —  —  —  0.6  —  —  0.4  —  1.0 
Share-based compensation expense —  —  —  —  9.3  —  —  —  —  9.3 
Treasury stock repurchase (0.2) —  0.2  —  —  —  —  (47.8) —  (47.8)
Balance at April 30, 2020 49.1  $ 4.9  4.3  $ 0.4  $ 1,626.5  $ (512.8) $ 3,126.9  $ (618.6) $ 0.2  $ 3,627.5 


5


THE COOPER COMPANIES, INC. AND SUBSIDIARIES

Consolidated Condensed Statements of Stockholders' Equity
(In millions, unaudited)
Common Shares Treasury Stock Additional Paid-In Capital Accumulated
Other
Comprehensive
Income (Loss)
Retained Earnings Treasury Stock Noncontrolling Interests Total
Stockholders'
Equity
Shares Amount Shares Amount
Balance at November 1, 2020 49.1  $ 4.9  4.3  $ 0.4  $ 1,646.8  $ (472.0) $ 3,261.8  $ (617.3) $ 0.2  $ 3,824.8 
Net income attributable to Cooper stockholders —  —  —  —  —  —  2,101.1  —  —  2,101.1 
Other comprehensive income, net of tax —  —  —  —  —  90.7  —  —  —  90.7 
Issuance of common stock for stock plans, net 0.1  —  —  —  (11.0) —  —  —  —  (11.0)
Issuance of common stock for employee stock purchase plan —  —  —  —  0.8  —  —  0.6  —  1.4 
Dividends on common stock ($0.03 per share)
—  —  —  —  —  —  (1.5) —  —  (1.5)
Share-based compensation expense —  —  —  —  10.6  —  —  —  —  10.6 
Treasury stock repurchase (0.1) —  0.1  —  —  —  —  (24.8) —  (24.8)
ASU 2016-13 adoption —  —  —  —  —  —  (1.4) —  —  (1.4)
Balance at January 31, 2021 49.1  $ 4.9  4.4  $ 0.4  $ 1,647.2  $ (381.3) $ 5,360.0  $ (641.5) $ 0.2  $ 5,989.9 
Net income attributable to Cooper stockholders —  —  —  —  —  —  117.5  —  —  117.5 
Other comprehensive income, net of tax —  —  —  —  —  34.1  —  —  —  34.1 
Issuance of common stock for stock plans, net 0.1  0.1  —  —  9.7  —  —  —  —  9.8 
Issuance of common stock for employee stock purchase plan —  —  —  —  0.9  —  —  0.6  —  1.5 
Share-based compensation expense —  —  —  —  10.0  —  —  —  —  10.0 
Treasury stock repurchase —  —  —  —  —  —  —  —  —  — 
Balance at April 30, 2021 49.2  $ 5.0  4.4  $ 0.4  $ 1,667.8  $ (347.2) $ 5,477.5  $ (640.9) $ 0.2  $ 6,162.8 


The accompanying notes are an integral part of these Consolidated Condensed Financial Statements.

6



THE COOPER COMPANIES, INC. AND SUBSIDIARIES

Consolidated Condensed Statements of Cash Flows
Six Months Ended April 30,
(In millions, unaudited)
2021 2020
Cash flows from operating activities:
Net income $ 2,218.6  $ 102.0 
Depreciation and amortization 153.0  139.4 
Increase in operating capital (61.4) (119.8)
Deferred income taxes (1,977.6) (3.6)
Other non-cash items 7.7  37.5 
Net cash provided by operating activities 340.3  155.5 
Cash flows from investing activities:
Purchases of property, plant and equipment (105.8) (158.3)
Acquisitions of businesses and assets, net of cash acquired, and other (170.9) (11.2)
Net cash used in investing activities (276.7) (169.5)
Cash flows from financing activities:
Proceeds from long-term debt 486.3  1862.0 
Repayments of long-term debt (545.6) (1,781.3)
Net proceeds (repayments) from short-term debt 5.4  (10.0)
Net (payments) proceeds related to share-based compensation awards (1.3) (8.4)
Dividends on common stock (1.5) (1.5)
Repurchase of common stock (24.8) (47.8)
Issuance of common stock for employee stock purchase plan 2.5  0.9 
Debt issuance costs —  (5.5)
Net cash provided by (used in) financing activities (79.0) 8.4 
Effect of exchange rate changes on cash, cash equivalents and restricted cash 5.0  (3.1)
Net increase in cash, cash equivalents and restricted cash (10.4) (8.7)
Cash, cash equivalents and restricted cash at beginning of period 116.8  89.5 
Cash, cash equivalents and restricted cash at end of period $ 106.4  $ 80.8 
Reconciliation of cash flow information:
Cash and cash equivalents $ 105.9  $ 79.8 
Restricted cash included in other current assets 0.5  1.0 
Total cash, cash equivalents and restricted cash $ 106.4  $ 80.8 

The accompanying notes are an integral part of these Consolidated Condensed Financial Statements.

7

THE COOPER COMPANIES, INC. AND SUBSIDIARIES
Notes to Consolidated Condensed Financial Statements
(Unaudited)
Note 1. General

The accompanying Consolidated Condensed Financial Statements of the Cooper Companies, Inc. and its subsidiaries (the Company) have been prepared in accordance with generally accepted accounting principles in the United States ("GAAP") for interim financial information and with the requirements of Regulation S-X, Rule 10-01 for financial statements required to be filed as a part of this Quarterly Report on Form 10-Q. Unless the context requires otherwise, terms "the Company", "we", "us", and "our" are used to refer collectively to the Cooper Companies, Inc. and its subsidiaries.

The accompanying Consolidated Condensed Financial Statements and related notes are unaudited and should be read in conjunction with the audited Consolidated Financial Statements of the Cooper Companies, Inc. and its subsidiaries (the Company) and related notes as contained in the Company’s Annual Report on Form 10-K for the fiscal year ended October 31, 2020. The Consolidated Condensed Financial Statements include all adjustments (consisting only of normal recurring adjustments) and accruals necessary in the judgment of management for a fair presentation of the results for the interim periods presented. Readers should not assume that the results reported here either indicate or guarantee future performance.
Accounting Policies

There have been no material changes to our significant accounting policies described in our Annual Report on Form 10-K for the fiscal year ended October 31, 2020.
Estimates

The World Health Organization categorized the Coronavirus disease 2019 (COVID-19) as a pandemic. The COVID-19 pandemic has caused a severe global health crisis, along with economic and societal disruptions and uncertainties, which have negatively impacted business and healthcare activity globally. As a result of healthcare systems responding to the demands of managing the pandemic, governments around the world imposing measures designed to reduce the transmission of the COVID-19 virus, and individuals responding to the concerns of contracting the COVID-19 virus, many optical practitioners & retailers, hospitals, medical offices and fertility clinics closed their facilities, restricted access, or delayed or canceled patient visits, exams and elective medical procedures, and many customers that have reopened are experiencing reduced patient visits. These factors have had, and in the future may have, an adverse effect on our sales, operating results and cash flows.
The preparation of Consolidated Condensed Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of net sales and expenses during the reporting period. Actual results could differ from those estimates particularly as it relates to estimates reliant on forecasts and other assumptions reasonably available to the Company and the uncertain future impacts of the COVID-19 pandemic and related economic disruptions. The extent to which the COVID-19 pandemic and related economic disruptions impact our business and financial results will depend on future developments including, but not limited to, the continued spread, duration and severity of the COVID-19 pandemic; the occurrence, spread, duration and severity of any subsequent wave or waves of outbreaks; the actions taken by the U.S. and foreign governments to contain the COVID-19 pandemic, address its impact or respond to the reduction in global and local economic activity; the occurrence, duration and severity of a global, regional or national recession, depression or other sustained adverse market event; the impact of the developments described above on our customers and suppliers; and how quickly and to what extent normal economic and operating conditions can resume. The accounting matters assessed included, but were not limited to:
allowance for doubtful accounts and credit losses
the carrying value of inventory
the carrying value of goodwill and other long-lived assets
There was not a material impact to the above estimates in the Company’s Consolidated Condensed Financial Statements for the three and six months ended April 30, 2021. The Company continually monitors and evaluates the estimates used as additional information becomes available. Adjustments will be made to these provisions periodically to reflect new facts and circumstances that may indicate that historical experience may not be indicative of current and/or future results. The Company’s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in material
8

THE COOPER COMPANIES, INC. AND SUBSIDIARIES
Notes to Consolidated Condensed Financial Statements
(Unaudited)
changes to the estimates and material impacts to the Company’s Consolidated Condensed Financial Statements in future reporting periods.
Accounting Pronouncements Recently Adopted

In January 2020, the Financial Accounting Standards Board (FASB) issued ASU 2020-01, Investments-Equity Securities (Topic 321), Investments-Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815)—Clarifying the Interactions between Topic 321, Topic 323, and Topic 815. This guidance addresses accounting for the transition into and out of the equity method and provides clarification of the interaction of rules for equity securities, the equity method of accounting, and forward contracts and purchase options on certain types of securities. This standard is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2020. Early adoption is permitted. The Company early adopted this guidance in the second quarter of fiscal 2021, and it did not have a material impact on our Consolidated Condensed Financial Statements.

In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments and subsequent amendments to the initial guidance: ASU 2018-19 Codification Improvements to Topic 326, Financial Instruments-Credit Losses, ASU 2019-04 Codification Improvements to Topic 326, Financial Instruments-Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments, ASU 2019-05 Financial Instruments-Credit Losses, ASU 2019-11 Codification Improvements to Topic 326, Financial Instruments—Credit Losses, ASU 2020-02 Financial Instruments—Credit Losses (Topic 326) and Leases (Topic 842) and ASU 2020-03 Codification Improvements to Financial Instruments (collectively, “Topic 326”). Topic 326 requires measurement and recognition of expected credit losses for financial assets held. Topic 326 is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2019. The Company adopted this guidance in the first quarter of fiscal 2021 on a modified retrospective basis, and the most notable impact was related to the assessment of the adequacy of its allowance for doubtful accounts on trade accounts receivable and the recognition of credit losses. The Company recorded a cumulative-effect adjustment of $1.4 million to the Consolidated Condensed Balance Sheet on November 1, 2020.

In November 2018, the FASB issued ASU 2018-18, Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606. This guidance amended Topic 808 and Topic 606 to clarify that transactions in a collaborative arrangement should be accounted for under Topic 606 when the counterparty is a customer for a distinct good or service (i.e., unit of account). The amendments preclude an entity from presenting consideration from a transaction in a collaborative arrangement as revenue from contracts with customers if the counterparty is not a customer for that transaction. This guidance is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2019. The Company adopted this guidance on November 1, 2020, and it did not have a material impact on our Consolidated Condensed Financial Statements.

Accounting Pronouncements Issued Not Yet Adopted

In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. This guidance removes certain exceptions to the general principles in Topic 740 and enhances and simplifies various aspects of the income tax accounting guidance, including requirements such as tax basis step-up in goodwill obtained in a transaction that is not a business combination, ownership changes in investments, and interim-period accounting for enacted changes in tax law. This standard is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2020. Early adoption is permitted. We are currently evaluating the impact of ASU 2019-12 on our Consolidated Condensed Financial Statements, which is effective for the Company in our fiscal year and interim periods beginning on November 1, 2021.
In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting and subsequent amendment to the initial guidance: ASU 2021-01, Reference Rate Reform (Topic 848): Scope (collectively, “Topic 848”). Topic 848 provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The amendments apply only to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. The guidance generally can be applied from March 12, 2020 through December 31, 2022. We are currently assessing the impacts of the practical expedients provided in Topic 848 and which, if any, we will adopt.
9

THE COOPER COMPANIES, INC. AND SUBSIDIARIES
Notes to Consolidated Condensed Financial Statements
(Unaudited)
In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40). This update amends the guidance on convertible instruments and the derivatives scope exception for contracts in an entity's own equity and improves and amends the related EPS guidance for both Subtopics. This standard is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2021, which means it will be effective for our fiscal year beginning November 1, 2022. Early adoption is permitted but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. We are currently evaluating the impact of ASU 2020-06 on our Consolidated Condensed Financial Statements.
No other recently issued accounting pronouncements had or are expected to have a material impact on our Consolidated Condensed Financial Statements.

Note 2. Acquisitions
The following is a summary of the allocation of the total purchase consideration for business and asset acquisitions that the Company completed during the six months ended April 30, 2021 and fiscal 2020:
(In millions) April 30, 2021 October 31, 2020
Technology $ 163.5  $ — 
In-Process Research & Development (IPR&D) 20.0  — 
Customer relationships 5.5  11.4 
Trademarks 1.3  5.1 
Other 0.4  3.9 
Total identifiable intangible assets $ 190.7  $ 20.4 
Goodwill 49.7  15.3 
Net tangible assets (liabilities) (13.0) (0.3)
Fair value of contingent consideration (38.6) — 
Total closing purchase price $ 188.8  $ 35.4 
All acquisitions were funded by cash generated from operations or facility borrowings.
For business acquisitions, the Company recorded tangible and intangible assets acquired and liabilities assumed at their fair values as of the applicable date of acquisition. For asset acquisitions, the Company recorded tangible and intangible assets acquired and liabilities assumed at their estimated and relative fair values as of the applicable date of acquisition.

The Company believes these acquisitions strengthen CooperSurgical's and CooperVision's businesses through the addition of new distributors or complementary products and services.
Fiscal Year 2021

On April 26, 2021, CooperVision completed the acquisition of a privately-held U.K. contact lens manufacturer focusing on specialty contact lenses. This acquisition expands CooperVision’s specialty eye care portfolio and accelerates its development of myopia management solutions in the U.K. The purchase price allocation is preliminary, and the Company is in the process of finalizing information and the corresponding impact on goodwill.

On March 1, 2021, CooperSurgical completed the acquisition of a privately-held medical device company that designed and developed an innovative obstetric product for use in urgent obstetrics to reduce risks associated with childbirth. The purchase price allocation is preliminary, and the Company is in the process of finalizing information and the corresponding impact on goodwill.

On February 1, 2021, CooperSurgical acquired all of the remaining equity interests of a privately-held medical device company that developed the Mara® Water Vapor Ablation System, which is used for endometrial ablation. The Company accounted for this acquisition as an asset acquisition, whereby the Company allocated the total cost of the acquisition to the net assets acquired on the basis of their estimated relative fair values on the acquisition date with no goodwill recognized. The primary asset acquired in this asset acquisition is Technology.

On January 19, 2021, CooperVision acquired all of the remaining equity interests of a privately-held medical device company that develops spectacle lenses for myopia management. The fair value remeasurement of our previous equity investment immediately before the acquisition resulted in a gain of $11.5 million, which was recorded in other income. The
10

THE COOPER COMPANIES, INC. AND SUBSIDIARIES
Notes to Consolidated Condensed Financial Statements
(Unaudited)
terms of the acquisition include upfront cash consideration paid at closing of approximately $40.9 million attributable to the equity interests not held by the Company on the closing date. The transaction also includes potential payments of future consideration that are contingent upon the achievement of the regulatory approval milestone (the regulatory approval payment) and the acquired business reaching certain revenue thresholds over a specified period (the revenue payments). The undiscounted range of the contingent consideration is zero to $139.1 million payable to the other former equity interest owners. The purchase price allocation is preliminary, and the Company is in the process of finalizing information primarily related to taxes and the corresponding impact on goodwill.

The estimated fair value of the contingent consideration on the acquisition date was approximately $37.9 million, and, accordingly, the Company recorded a liability of approximately $30.2 million, which represents the fair value of the contingent consideration payable to the other former equity interest owners. The fair value of the regulatory approval payment was determined using an option pricing framework based on the expected payment under the contractual terms and the estimates of the probability of achieving the regulatory approval. The fair value of the revenue payments was determined using a Monte Carlo simulation based on the revenue projections and the expected payment for each simulation.

As of April 30, 2021, no contingent consideration has been paid. The Company remeasured the fair value of the contingent consideration as of April 30, 2021 and determined the fair value of the contingent consideration has not changed since the acquisition date. Therefore, no fair value adjustment was recognized in the Consolidated Statements of Income and Comprehensive Income for the three months ended April 30, 2021.
On December 31, 2020, CooperSurgical completed the acquisition of a privately-held in vitro fertilization (IVF) cryo-storage software solutions company. The purchase price allocation is preliminary, and the Company is in the process of finalizing information and the corresponding impact on goodwill.
The pro forma results of operations of these acquisitions have not been presented because the effect of the business combinations described above was not material to the consolidated results of operations.
Fiscal Year 2020

On August 7, 2020, CooperVision completed the acquisition of a privately-held U.S. contact lens manufacturer focusing on ortho-k lenses. This acquisition expands CooperVision’s specialty eye care portfolio and its leadership in addressing the increasing severity and prevalence of myopia. The purchase price allocation is preliminary, and the Company is in the process of finalizing information and the corresponding impact on goodwill.

On December 13, 2019, CooperSurgical completed the acquisition of a privately-held distributor of IVF medical devices and systems.

The pro forma results of operations of these acquisitions have not been presented because the effect of the business combination described above was not material to the consolidated results of operations.

Contingent Consideration

Certain of the Company’s business combinations involve potential payments of future consideration that are contingent upon the achievement of regulatory milestones and/or the acquired business reaching certain revenue thresholds. A liability is recorded for the estimated fair value of the contingent consideration on the acquisition date. The fair value of the contingent consideration is remeasured at each reporting period, and the change in fair value is recognized in selling, general and administrative expense in the Consolidated Statements of Income and Comprehensive Income.

The following table provides a reconciliation of the beginning and ending balances of contingent consideration:

Periods Ended April 30, Three Months Six Months
(In millions) 2021 2020 2021 2020
Beginning balance $ 30.2  $ —  $ —  $ — 
Purchase price contingent consideration 0.6  —  30.8  — 
Payments —  —  —  — 
Change in fair value —  —  —  — 
Ending balance $ 30.8  $ —  $ 30.8  $ — 


11

THE COOPER COMPANIES, INC. AND SUBSIDIARIES
Notes to Consolidated Condensed Financial Statements
(Unaudited)
Note 3. Inventories
(In millions) April 30, 2021 October 31, 2020
Raw materials $ 143.6  $ 151.0 
Work-in-process 13.8  12.4 
Finished goods 424.6  407.0 
Total inventories $ 582.0  $ 570.4 
Inventories are stated at the lower of cost and net realizable value. Cost is computed using standard cost that approximates actual cost, on a first-in, first-out basis.

Note 4. Intangible Assets

Goodwill
(In millions) CooperVision CooperSurgical Total
Balance at October 31, 2020 $ 1,779.3  $ 668.0  $ 2,447.3 
Current period additions 31.1  18.6  49.7 
Foreign currency translation adjustment 63.5  7.2  70.7 
Balance at April 30, 2021 $ 1,873.9  $ 693.8  $ 2,567.7 

The Company evaluates goodwill for impairment annually during the fiscal third quarter and when an event occurs or circumstances change such that it is reasonably possible that impairment may exist. The Company accounts for goodwill, evaluates and tests goodwill balances for impairment in accordance with related accounting standards.

The Company performed an annual impairment assessment in the third quarter of fiscal 2020, and its analysis indicated that there was no impairment of goodwill in reporting units.
Other Intangible Assets
  April 30, 2021 October 31, 2020
(In millions) Gross 
Carrying
Amount
Accumulated
Amortization
Gross 
Carrying
Amount
Accumulated
Amortization
Weighted Average Amortization Period
(in years)
Intangible assets with definite lives:
Composite intangible asset $ 1,061.9  $ 247.8  $ 1,061.9  $ 212.4  15
Technology 564.8  270.1  401.2  251.9  11
Customer relationships 378.3  229.7  367.0  216.2  13
Trademarks 155.9  43.3  153.4  37.7  14
License and distribution rights and other 32.2  19.9  31.8  18.2  10
2,193.1  $ 810.8  2,015.3  $ 736.4  14
Less: accumulated amortization and translation 810.8  736.4 
Intangible assets with definite lives, net 1,382.3  1,278.9 
Intangible assets with indefinite lives, net (1)
30.1  10.1 
Total other intangibles, net $ 1,412.4  $ 1,289.0 
(1) Intangible assets with indefinite lives include technology and trademarks.
Balances include foreign currency translation adjustments.
12

THE COOPER COMPANIES, INC. AND SUBSIDIARIES
Notes to Consolidated Condensed Financial Statements
(Unaudited)
As of April 30, 2021, the estimate of future amortization expenses for intangible assets with definite lives is as follows:
Fiscal Years: (In millions)
Remainder of 2021 $ 76.7 
2022 151.6 
2023 149.3 
2024 145.1 
2025 134.6 
Thereafter 725.0 
Total remaining amortization for intangible assets with definite lives $ 1,382.3 
The Company assesses definite-lived intangible assets whenever events or changes in circumstances indicate that the carrying amount of a definite-lived intangible asset (asset group) may not be recoverable. When events or changes in circumstances indicate that the carrying amount of a definite-lived intangible asset may not be recoverable, in accordance with related accounting standards, the Company evaluates whether the definite-lived intangible asset is impaired by comparing its carrying value to its undiscounted future cash flows.
The Company assesses indefinite-lived intangible assets annually in the third quarter of the fiscal year, or whenever events or circumstances indicate that the carrying amount of an indefinite-lived intangible asset (asset group) may not be recoverable, in accordance with related accounting standards. The Company evaluates whether the indefinite-lived intangible asset is impaired by comparing its carrying value to its fair value.
The Company performed an annual impairment assessment in the third quarter of fiscal 2020 and did not recognize any intangible asset impairment charges.

Note 5. Debt
(In millions) April 30, 2021 October 31, 2020
Overdraft and other credit facilities $ 62.7  $ 59.4 
Term loan 350.0  350.0 
Less: unamortized debt issuance cost (0.1) (0.1)
Short-term debt $ 412.6  $ 409.3 
Revolving credit 475.0  534.0 
Term loans 850.0  850.0 
Other 0.2  0.2 
Less: unamortized debt issuance cost (0.3) (0.3)
Long-term debt 1,324.9  1,383.9 
Total debt $ 1,737.5  $ 1,793.2 
    
Term Loan Agreement on October 16, 2020

On October 16, 2020, the Company entered into a 364-day, $350.0 million, term loan agreement by and among the Company, the lenders party thereto and The Bank of Nova Scotia, as administrative agent which matures on October 15, 2021. The funds were used to partially repay outstanding borrowings under the 2020 Revolving Credit Facility (as defined below). At April 30, 2021, the Company had $350.0 million outstanding under this agreement.

Amounts outstanding under this agreement will bear interest, at the Company’s option, at either the base rate, or the adjusted LIBO rate, plus, in each case, an applicable rate of 0.00% in respect of base rate loans and 0.80% in respect of adjusted LIBO rate loans. The interest rate was 0.92% at April 30, 2021.

13

THE COOPER COMPANIES, INC. AND SUBSIDIARIES
Notes to Consolidated Condensed Financial Statements
(Unaudited)
This agreement contains customary restrictive covenants, as well as financial covenants that require the Company to maintain a certain Total Leverage Ratio and Interest Coverage Ratio consistent with the 2020 Credit Agreement discussed below.
Revolving Credit and Term Loan Agreement on April 1, 2020
On April 1, 2020, the Company entered into a Revolving Credit and Term Loan Agreement (the 2020 Credit Agreement), among the Company, CooperVision International Holding Company, LP, CooperSurgical Netherlands B.V., CooperVision Holding Kft. the lenders from time to time party thereto, and KeyBank National Association, as administrative agent. The 2020 Credit Agreement provides for (a) a multicurrency revolving credit facility (the 2020 Revolving Credit Facility) in an aggregate principal amount of $1.29 billion and (b) a term loan facility (the 2020 Term Loan Facility) in an aggregate principal amount of $850.0 million, each of which, unless terminated earlier, mature on April 1, 2025. In addition, the Company has the ability from time to time to request an increase to the size of the revolving credit facility or establish one or more new term loans under the term loan facility in an aggregate amount up to $1.605 billion, subject to the discretionary participation of the lenders.
Amounts outstanding under the 2020 Credit Agreement will bear interest, at the Company’s option, at either the base rate, or the adjusted LIBO rate or adjusted foreign currency rate, plus, in each case, an applicable rate of between 0.00% and 0.50% in respect of base rate loans, and between 0.75% and 1.50% in respect of adjusted LIBO rate or adjusted foreign currency rate loans, in each case in accordance with a pricing grid tied to the Total Leverage Ratio, as defined in the 2020 Credit Agreement. During the term of the 2020 Revolving Credit Facility, the Borrowers may borrow, repay and re-borrow amounts available under the Revolving Credit Facility, subject to voluntary reduction of the revolving commitment.
The Company pays an annual commitment fee that ranges from 0.10% to 0.20% of the unused portion of the 2020 Revolving Credit Facility based upon the Company’s Total Leverage Ratio, as defined in the 2020 Credit Agreement. In addition to the annual commitment fee, the Company is also required to pay certain letter of credit and related fronting fees and other administrative fees pursuant to the terms of the 2020 Credit Agreement.
On April 1, 2020, the Company borrowed $850.0 million under the 2020 Term Loan Facility and $445.0 million under the 2020 Revolving Credit Facility and used the proceeds to repay the outstanding amounts under the previous credit agreement and an outstanding term loan, and for general corporate purposes.
On October 30, 2020, the Company entered into Amendment No. 1 to the 2020 Credit Agreement (the First Amendment to the 2020 Credit Agreement). The First Amendment to the 2020 Credit Agreement modifies the 2020 Credit Agreement by, among other things, adding CooperVision International Limited as a revolving borrower and releasing certain borrowers in the 2020 Credit Agreement.
At April 30, 2021, the Company had $850.0 million outstanding under the 2020 Term Loan Facility, $475.0 million outstanding under the 2020 Revolving Credit Facility and $813.6 million available under the 2020 Revolving Credit Facility, net of $1.4 million outstanding letters of credit. The interest rate on the 2020 Term Loan Facility was 1.12% at April 30, 2021. During the three and six months ended April 30, 2021, the Company expensed less than $0.1 million related to the debt issuance costs of the 2020 Term Loan Facility.
The 2020 Credit Agreement contains customary restrictive covenants, as well as financial covenants that require the Company to maintain a certain Total Leverage Ratio and Interest Coverage Ratio, each as defined in the 2020 Credit Agreement:
Interest Coverage Ratio, as defined, to be at least 3.00 to 1.00 at all times.
Total Leverage Ratio, as defined, to be no higher than 3.75 to 1.00.
At April 30, 2021, the Company was in compliance with the Interest Coverage Ratio at 36.81 to 1.00 and the Total Leverage Ratio at 1.78 to 1.00 for the 2020 Credit Agreement. The Company, after considering the potential impacts of the COVID-19 pandemic, expects to remain in compliance with its financial maintenance covenant and meet its debt service obligations for at least the twelve months following the date of issuance of these financial statements.
Refer to our Annual Report on Form 10-K for the fiscal year ended October 31, 2020 for more details.

14

THE COOPER COMPANIES, INC. AND SUBSIDIARIES
Notes to Consolidated Condensed Financial Statements
(Unaudited)
The following is a summary of the maximum commitments and the net amounts available to us under credit facilities discussed above as of April 30, 2021:
(In millions) Facility Limit Outstanding Borrowings Outstanding Letters of Credit Total Amount Available Maturity Date
2020 Revolving Credit Facility $ 1,290.0  $ 475.0  $ 1.4  $ 813.6  April 1, 2025
2020 Term Loan Facility 850.0  850.0  n/a —  April 1, 2025
2020 Term Loan 350.0  350.0  n/a —  October 15, 2021
Total $ 2,490.0  $ 1,675.0  $ 1.4  $ 813.6 

Note 6. Income Taxes

The Company's effective tax rates for the three months ended April 30, 2021 and April 30, 2020 were 13.8% and (27.7)%, respectively. The increase was primarily due to changes in the geographical composition of pre-tax earnings. The Company's effective tax rate for the second quarter of fiscal 2021 was lower than the U.S. federal statutory tax rate primarily due to earnings in foreign jurisdictions with lower tax rates and excess tax benefits from share-based compensation.

The Company's effective tax rates for the six months ended April 30, 2021 and April 30, 2020 were (704.2)% and 4.2%, respectively. The decrease was primarily due to an intra-group transfer of intellectual property, as discussed below. The Company's effective tax rate for the six months ended April 30, 2021 was lower than the U.S. federal statutory tax rate primarily due to the intra-group transfer. The Company's effective tax rates for the six months ended April 30, 2021 and April 30, 2020 were otherwise lower than the U.S. federal statutory tax rate primarily due to earnings in foreign jurisdictions with lower tax rates and excess tax benefits from share-based compensation.

In November 2020, the Company completed an intra-group transfer of certain intellectual property and related assets to a UK subsidiary as part of a group restructuring to establish headquarters operations in the UK. Income before income taxes resulting from this transfer is eliminated upon consolidation. The transfer resulted in a step-up of the UK tax-deductible basis in the intellectual property and goodwill, creating a temporary difference between the book basis and the tax basis of these assets. As a result, the Company recognized a deferred tax asset of $1,987.9 million, with a corresponding income tax benefit, during the three months ended January 31, 2021.

Note 7. Earnings Per Share
Periods Ended April 30, Three Months Six Months
(In millions, except per share amounts) 2021 2020 2021 2020
Net income $ 117.5  $ 11.5  $ 2,218.6  $ 102.0 
Basic:
Weighted average common shares 49.2  49.2  49.2  49.2 
Basic earnings per share $ 2.39  $ 0.23  $ 45.12  $ 2.07 
Diluted:
Weighted average common shares 49.2  49.2  49.2  49.2 
Effect of dilutive stock options 0.5  0.4  0.5  0.5 
Diluted weighted average common shares 49.7  49.6  49.7  49.7 
Diluted earnings per share $ 2.36  $ 0.23  $ 44.65  $ 2.05 
15

THE COOPER COMPANIES, INC. AND SUBSIDIARIES
Notes to Consolidated Condensed Financial Statements
(Unaudited)
The following table sets forth stock options to purchase our common stock and restricted stock units that were not included in the diluted earnings per share calculation because their effect would have been antidilutive for the periods presented:
Periods Ended April 30, Three Months Six Months
(In thousands, except exercise prices) 2021 2020 2021 2020
Stock option shares excluded 108  210  108  207 
Range of exercise prices $ 345.74 
$254.77 – $304.54
$ 345.74  $ 304.54 
Restricted stock units excluded — 

Note 8. Share-Based Compensation Plans
The Company has several share-based compensation plans that are described in the Company’s Annual Report on Form 10‑K for the fiscal year ended October 31, 2020. The compensation expense and related income tax benefit recognized in our Consolidated Statements of Income and Comprehensive Income for share-based awards were as follows:
Periods Ended April 30, Three Months Six Months
(In millions) 2021 2020 2021 2020
Selling, general and administrative expense $ 8.7  $ 8.3  $ 17.8  $ 17.0 
Cost of sales 0.9  1.1  2.0  2.1 
Research and development expense 0.6  0.6  1.2  1.2 
Total share-based compensation expense $ 10.2  $ 10.0  $ 21.0  $ 20.3 
Related income tax benefit $ 1.2  $ 1.1  $ 2.4  $ 2.5 

Note 9. Stockholders’ Equity
Analysis of Changes in Accumulated Other Comprehensive (Loss) Income:
(In millions) Foreign Currency Translation Adjustment Minimum Pension Liability Derivative Instruments Total
Balance at October 31, 2019 $ (403.2) $ (43.9) $ —  $ (447.1)
Gross change in value 0.9  (16.8) (17.1) (33.0)
Tax effect for the period —  4.0  4.1  8.1 
Balance at October 31, 2020 $ (402.3) $ (56.7) $ (13.0) $ (472.0)
Gross change in value 105.3  —  25.9  131.2 
Tax effect for the period (0.2) —  (6.2) (6.4)
Balance at April 30, 2021 $ (297.2) $ (56.7) $ 6.7  $ (347.2)
Share Repurchases
In December 2011, our Board of Directors authorized the 2012 Share Repurchase Program and through subsequent amendments, the most recent in March 2017, the total repurchase authorization was increased from $500.0 million to $1.0 billion of the Company's common stock. This program has no expiration date and may be discontinued at any time. Purchases under the 2012 Share Repurchase Program are subject to a review of the circumstances in place at the time and may be made from time to time as permitted by securities laws and other legal requirements.
During the three months ended April 30, 2021, there were no share repurchases under the program. During the six months ended April 30, 2021, the Company repurchased 69.6 thousand shares of its common stock for $24.8 million, at an average purchase price of $356.61 per share.
At April 30, 2021, $334.8 million remained authorized for repurchase under the program.
16

THE COOPER COMPANIES, INC. AND SUBSIDIARIES
Notes to Consolidated Condensed Financial Statements
(Unaudited)
During the six months ended April 30, 2020, the Company repurchased 160.8 thousand shares of its common stock for $47.8 million, at an average purchase price of $296.88 per share, all repurchased in the second quarter of fiscal 2020.
Dividends    
The Company paid a semiannual dividend of approximately $1.5 million or 3 cents per share, on February 9, 2021, to stockholders of record on January 22, 2021. The Company paid a semiannual dividend of approximately $1.5 million or 3 cents per share, on February 10, 2020, to stockholders of record on January 23, 2020.

Note 10. Fair Value Measurements
Accounting standards define fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy prioritizes the inputs to valuation techniques used to measure fair value. An asset’s or liability’s level is based on the lowest level of input that is significant to the fair value measurement. Assets and liabilities carried at fair value are valued and disclosed in one of the following three levels of the valuation hierarchy:
Level 1: Quoted market prices in active markets for identical assets or liabilities.
Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data.
Level 3: Unobservable inputs reflecting the reporting entity’s own assumptions.
At April 30, 2021 and October 31, 2020, the carrying value of cash and cash equivalents, accounts receivable, prepaid expense and other current assets, lines of credit, accounts payable and other current liabilities approximates fair value due to the short-term nature of such instruments and the ability to obtain financing on similar terms.

The carrying value of our revolving credit facility and term loans approximates fair value based on current market rates (Level 2). On April 6, 2020 the Company entered into six interest rate swap contracts which are used to hedge the Company’s exposure to changes in cash flows associated with its variable rate debt and are designated as derivatives in a cash flow hedge. The payment streams are based on a total notional amount of $1.5 billion at the inception of the contracts. The interest rate swap contracts had maturities of seven years or less. As of April 30, 2021, two of the six interest rate swap contracts have matured and the outstanding contracts have a total notional amount of $1.1 billion.

The gain or loss on the derivatives is recorded as a component of accumulated other comprehensive income and subsequently reclassified into interest expense in the same period during which the hedged transaction affects earnings.

The fair value of the interest rate swap contracts is measured on a recurring basis by netting the discounted future fixed cash payments and the discounted expected variable cash receipts. The variable cash receipts are based on the expectation of future interest rates (forward curves) derived from observable market interest rate curves. The interest rate swap contracts were categorized as Level 2 in the fair value hierarchy, as the inputs to the derivative pricing model are generally observable and do not contain a high level of subjectivity. Refer to Note 14. Financial Derivatives and Hedging for further information.

The Company did not have any cross currency swaps or foreign currency forward contracts as of April 30, 2021 and October 31, 2020.
Nonrecurring fair value measurements

The Company uses fair value measures when determining assets and liabilities acquired in an acquisition as described in Note 2. Acquisitions which are considered a Level 3 measurement.

Note 11. Employee Benefits
The Company's Retirement Income Plan (the Plan), a defined benefit plan, covers substantially all full-time United States employees. The Company's contributions are designed to fund normal cost on a current basis and to fund the estimated prior service cost of benefit improvements. The unit credit actuarial cost method is used to determine the annual cost. The Company pays the entire cost of the Plan and funds such costs as they accrue. Virtually all of the assets of the Plan are comprised of equities and participation in equity and fixed income funds.
17

THE COOPER COMPANIES, INC. AND SUBSIDIARIES
Notes to Consolidated Condensed Financial Statements
(Unaudited)
The Company's results of operations for the three and six months ended April 30, 2021 and 2020, reflect the following components of net periodic defined benefit costs:
Periods Ended April 30, Three Months Six Months
(In millions) 2021 2020 2021 2020
Service cost $ 4.3  $ 3.4  $ 8.6  $ 6.9 
Interest cost 1.1  1.4  2.2  2.6 
Expected return on plan assets (3.1) (2.7) (6.2) (5.4)
Recognized net actuarial loss 1.3  1.0  2.7  2.0 
Net periodic defined benefit plan cost $ 3.6  $ 3.1  $ 7.3  $ 6.1 
The Company did not contribute to the Plan in the first half of fiscal 2021 and due to COVID-19 the Company is uncertain of the amount the Company will contribute during the remainder of the year. The Company did not contribute to the Plan in the first half of fiscal 2020. The expected rate of return on Plan assets for determining net periodic benefit plan cost is 8%.

Note 12. Contingencies

The Company is involved in various lawsuits, claims and other legal matters from time to time that arise in the ordinary course of conducting business, including matters involving our products, intellectual property, supplier relationships, distributors, competitor relationships, employees and other matters. The Company does not believe that the ultimate resolution of these proceedings or claims pending against it could have a material adverse effect on its financial condition or results of operations. At each reporting period, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under ASC 450, Contingencies. Legal fees are expensed as incurred.

Note 13. Business Segment Information
The Company discloses information about its operating segments, which were established based on the way that management organizes segments within the Company for making operating decisions and assessing financial performance. The Company's two operating segments are described below.
CooperVision. Competes in the worldwide contact lens market by developing, manufacturing and marketing a broad range of products for contact lens wearers, featuring advanced materials and optics. CooperVision designs its products to solve vision challenges such as astigmatism, presbyopia, myopia, ocular dryness and eye fatigues, with a broad collection of spherical, toric and multifocal contact lenses.
CooperSurgical. Competes in the general health care market with a focus on advancing the health of women, babies and families through a diversified portfolio of products and services focusing on women's health and fertility.
The Company uses operating income, as presented in our financial reports, as the primary measure of segment profitability. The Company does not allocate costs from corporate functions to segment operating income. Items below operating income are not considered when measuring the profitability of a segment. The Company uses the same accounting policies to generate segment results as the Company does for our consolidated results.
Total identifiable assets are those used in continuing operations except cash and cash equivalents, which the Company includes as corporate assets.
18

THE COOPER COMPANIES, INC. AND SUBSIDIARIES
Notes to Consolidated Condensed Financial Statements
(Unaudited)
Segment information:
Periods Ended April 30, Three Months Six Months
(In millions) 2021 2020 2021 2020
CooperVision net sales by category:
Toric lens $ 172.8  $ 133.6  $ 335.1  $ 288.7 
Multifocal lens 58.0  45.1  115.7  96.9 
Single-use sphere lens 144.5  116.1  290.5  254.2 
Non single-use sphere, other 147.3  107.4  288.3  247.6 
Total CooperVision net sales $ 522.6  $ 402.2  $ 1,029.6  $ 887.4 
CooperSurgical net sales by category:
Office and surgical products $ 112.6  $ 69.6  $ 216.1  $ 168.0 
Fertility 84.3  53.1  154.3  115.7 
CooperSurgical net sales 196.9  122.7  370.4  283.7 
Total net sales $ 719.5  $ 524.9  $ 1,400.0  $ 1,171.1 
Operating income (loss):
CooperVision $ 131.7  $ 67.7  $ 259.2  $ 190.6 
CooperSurgical 23.1  (25.6) 40.6  (23.9)
Corporate (11.6) (13.5) (23.2) (27.0)
Total operating income 143.2  28.6  276.6  139.7 
Interest expense 6.1  12.8  12.5  24.4 
Other (income) expense, net 0.7  6.8  (11.8) 8.9 
Income before income taxes $ 136.4  $ 9.0  $ 275.9  $ 106.4 
(In millions) April 30, 2021 October 31, 2020
Total identifiable assets:
CooperVision $ 6,442.2  $ 4,236.3 
CooperSurgical 2,374.9  2,293.8 
Corporate 196.7  207.4 
Total $ 9,013.8  $ 6,737.5 


Geographic information:
Periods Ended April 30, Three Months Six Months
(In millions) 2021 2020 2021 2020
Net sales to unaffiliated customers by country of domicile:
United States $ 336.1  $ 222.5  $ 649.1  $ 516.0 
Europe 230.0  178.7  450.8  392.1 
Rest of world 153.4  123.7  300.1  263.0 
Total $ 719.5  $ 524.9  $ 1,400.0  $ 1,171.1 

19

THE COOPER COMPANIES, INC. AND SUBSIDIARIES
Notes to Consolidated Condensed Financial Statements
(Unaudited)
(In millions) April 30, 2021 October 31, 2020
Net property, plant and equipment by country of domicile:
United States $ 726.4  $ 721.3 
Europe 374.8  363.0 
Rest of world 208.8  197.6 
Total $ 1,310.0  $ 1,281.9 
 
Note 14. Financial Derivatives and Hedging

As part of the Company’s overall risk management practices the Company enters into financial derivatives, interest rate swaps designated as cash flow hedges, to hedge the Company’s exposure to changes in cash flows associated with its variable rate debt.
The Company records all derivatives on its Consolidated Condensed Balance Sheets at fair value. The accounting for changes in the fair value of derivatives depends on the intended use of the derivative, whether the Company has elected to designate a derivative in a hedging relationship and apply hedge accounting, and whether the hedging relationship has satisfied the criteria necessary to apply hedge accounting. All of the Company's derivatives have satisfied the criteria necessary to apply hedge accounting.
The gain or loss on derivative instruments designated and qualifying for cash flow hedge accounting is deferred in other comprehensive income. The changes in fair value for all trades that are not designated for hedge accounting are recognized in current period earnings. Deferred gains or losses from designated cash flow hedges are reclassified into earnings in the period that the hedged interest expense affects earnings. The effectiveness of cash flow hedges is assessed at inception and quarterly thereafter. The Company does not offset fair value amounts recognized for derivative instruments in its Consolidated Condensed Balance Sheets for presentation purposes.
Credit risk related to derivative transactions reflects the risk that a party to the transaction could fail to meet its obligation under the derivative contracts. Therefore, the Company’s exposure to the counterparty’s credit risk is generally limited to the amounts, if any, by which the counterparty’s obligations to the Company exceed the Company’s obligations to the counterparty. The Company’s policy is to enter into contracts only with financial institutions which meet certain minimum credit ratings to help mitigate counterparty credit risk.
As of October 31, 2020, the Company had five outstanding derivatives designated as hedging instruments. One of the contracts matured on April 1, 2021. As of April 30, 2021, the Company had the following outstanding derivatives designated as hedging instruments:
(In millions, except for number of instruments) Number of Instruments Notional Value
Interest Rate Swap Contracts 4 $ 1,100 
These contracts have remaining maturities of six years or less.

The pre-tax impact of gain on derivatives designated for hedge accounting recognized in other comprehensive income (loss) was $8.9 million ($6.7 million, net of tax) as of April 30, 2021.
20

THE COOPER COMPANIES, INC. AND SUBSIDIARIES
Notes to Consolidated Condensed Financial Statements
(Unaudited)
The following table summarizes the fair values of derivative instruments as of the periods indicated and the line items in the accompanying Consolidated Condensed Balance Sheets where the instruments are recorded:
Derivative Assets
(In millions) April 30, 2021 October 31, 2020
Derivatives designated as cash flow hedges Balance sheet location
Interest rate swap contracts Other current assets $ —  $ — 
Interest rate swap contracts Other non-current assets 9.5  — 
$ 9.5  $ — 
Derivative Liabilities
(In millions) April 30, 2021 October 31, 2020
Derivatives designated as cash flow hedges Balance sheet location
Interest rate swap contracts Other current liabilities $ 0.1  $ 0.6 
Interest rate swap contracts Other non-current liabilities 0.5  16.5 
$ 0.6  $ 17.1 
The following table summarizes the amounts recognized with respect to our derivative instruments within the accompanying Consolidated Statements of Income and Comprehensive Income:
Periods Ended April 30, Three Months Six Months
(In millions) 2021 2020 2021 2020
Derivatives designated as cash flow hedges Location of Loss Recognized on Derivatives
Interest rate swap contracts Interest expense $ 2.0  $ —  $ 4.1  $ — 
The Company expects that $6.4 million recorded as a component of accumulated other comprehensive income (loss) will be realized in the statements of earnings over the next twelve months and the amount will vary depending on prevailing interest rates.

The following table details the changes in accumulated other comprehensive income:
(In millions) Amount
Beginning balance gain / (loss) as of October 31, 2020 $ (17.1)
Amount recognized in other comprehensive income on interest rate swap contracts, gross ($16.6 million, net of tax)
21.9 
Amount reclassified from other comprehensive income into earnings, gross ($3.1 million, net of tax)
4.1 
Ending balance gain / (loss) as of April 30, 2021 $ 8.9 

21


THE COOPER COMPANIES, INC. AND SUBSIDIARIES

Item 2. Management’s Discussion and Analysis of Financial Condition
and Results of Operations
Note numbers refer to “Notes to Consolidated Condensed Financial Statements” in Item 1. Unaudited Financial Statements.
Forward-Looking Statements
This Quarterly Report on Form 10-Q contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These include statements relating to plans, prospects, goals, strategies, future actions, events or performance and other statements which are other than statements of historical fact, including all statements regarding the expected impact of the ongoing COVID-19 pandemic on our business; and statements regarding acquisitions including the acquired companies' financial position, market position, product development and business strategy, expected cost synergies, expected timing and benefits of the transaction, difficulties in integrating entities or operations, as well as estimates of our and the acquired entities' future expenses, sales and earnings per share are forward-looking. In addition, all statements regarding anticipated growth in our net sales, anticipated effects of any product recalls, anticipated market conditions, planned product launches and expected results of operations and integration of any acquisition are forward-looking. To identify these statements, look for words like “believes,” “outlook,” “probable,” “expects,” “may,” “will,” “should,” “could,” “seeks,” “intends,” “plans,” “estimates” or “anticipates” and similar words or phrases. Forward-looking statements necessarily depend on assumptions, data or methods that may be incorrect or imprecise and are subject to risks and uncertainties. Among the factors that could cause our actual results and future actions to differ materially from those described in forward-looking statements are:
The effects of the ongoing COVID-19 pandemic and related economic disruptions and new governmental regulations on our business, results of operations, cash flow and financial condition, including but not limited to the potential impact on our sales, operations and supply chain.
Adverse changes in the global or regional general business, political and economic conditions, including the impact of continuing uncertainty and instability of certain countries, that could adversely affect our global markets, and the potential adverse economic impact and related uncertainty caused by these items, including but not limited to, the ongoing COVID-19 pandemic, and escalating global trade barriers, including additional tariffs, by countries such as China.
Changes in tax laws or their interpretation, changes in statutory tax rates, and adverse outcomes in tax disputes including but not limited to, the U.S., the United Kingdom and other countries may affect our taxation of earnings recognized in foreign jurisdictions, result in unexpected tax liabilities, and/or negatively impact our effective tax rate.
Foreign currency exchange rate and interest rate fluctuations including the risk of fluctuations in the value of foreign currencies or interest rates that would decrease our net sales and earnings.
Our existing and future variable rate indebtedness and associated interest expense is impacted by rate increases, which could adversely affect our financial health or limit our ability to borrow additional funds.
Acquisition-related adverse effects including the failure to successfully obtain the anticipated net sales, margins and earnings benefits of acquisitions, integration delays or costs and the requirement to record significant adjustments to the preliminary fair value of assets acquired and liabilities assumed within the measurement period, required regulatory approvals for an acquisition not being obtained or being delayed or subject to conditions that are not anticipated, adverse impacts of changes to accounting controls and reporting procedures, contingent liabilities or indemnification obligations, increased leverage and lack of access to available financing (including financing for the acquisition or refinancing of debt owed by us on a timely basis and on reasonable terms).
Adverse changes in global political and economic conditions, and related uncertainty caused by the United Kingdom’s withdrawal from the European Union (EU) and its potential impact on, among other things, the movement of goods and materials in our supply chain, additional regulatory approvals and requirements, and increased tariffs and duties.
Compliance costs and potential liability in connection with U.S. and foreign laws and health care regulations pertaining to privacy and security of personal information, such as HIPAA and the California Consumer Privacy
22


THE COOPER COMPANIES, INC. AND SUBSIDIARIES
Item 2. Management’s Discussion and Analysis of Financial Condition
and Results of Operations
Act (CCPA) in the U.S. and the General Data Protection Regulation requirements in Europe, including but not limited to those resulting from data security breaches.
A major disruption in the operations of our manufacturing, accounting and financial reporting, research and development, distribution facilities or raw material supply chain due to the ongoing COVID-19 pandemic, integration of acquisitions, man-made or natural disasters, cybersecurity incidents or other causes.
A major disruption in the operations of our manufacturing, accounting and financial reporting, research and development or distribution facilities due to technological problems, including any related to our information systems maintenance, enhancements or new system deployments, integrations or upgrades.
Market consolidation of large customers globally through mergers or acquisitions resulting in a larger proportion or concentration of our business being derived from fewer customers.
Disruptions in supplies of raw materials, particularly components used to manufacture our silicone hydrogel lenses.
New U.S. and foreign government laws and regulations, and changes in existing laws, regulations and enforcement guidance, which affect areas of our operations including, but not limited to, those affecting the health care industry, including the contact lens industry specifically and the medical device or pharmaceutical industries generally, including but not limited to the EU Medical Devices Regulation, and the EU In Vitro Diagnostic Medical Devices Regulation.
Legal costs, insurance expenses, settlement costs and the risk of an adverse decision, prohibitive injunction or settlement related to product liability, patent infringement or other litigation.
Limitations on sales following product introductions due to poor market acceptance.
New competitors, product innovations or technologies, including but not limited to, technological advances by competitors, new products and patents attained by competitors, and competitors' expansion through acquisitions.
Reduced sales, loss of customers and costs and expenses related to product recalls and warning letters.
Failure to receive, or delays in receiving, regulatory approvals for products.
Failure of our customers and end users to obtain adequate coverage and reimbursement from third-party payors for our products and services.
The requirement to provide for a significant liability or to write off, or accelerate depreciation on, a significant asset, including goodwill, other intangible assets and idle manufacturing facilities and equipment.
The success of our research and development activities and other start-up projects.
Dilution to earnings per share from acquisitions or issuing stock.
Impact and costs incurred from changes in accounting standards and policies.
Environmental risks, including increasing environmental legislation and the broader impacts of climate change.
Other events described in our Securities and Exchange Commission filings, including the “Business” and “Risk Factors” sections in our Annual Report on Form 10-K for the fiscal year ended October 31, 2020, as such Risk Factors may be updated in quarterly filings including updates made in this filing.
We caution investors that forward-looking statements reflect our analysis only on their stated date. We disclaim any intent to update them except as required by law.


23


THE COOPER COMPANIES, INC. AND SUBSIDIARIES
Item 2. Management’s Discussion and Analysis of Financial Condition
and Results of Operations
Results of Operations

In this section, we discuss the results of our operations for the second quarter of fiscal 2021 ended April 30, 2021 and compare them with the same period of fiscal 2020. We discuss our cash flows and current financial condition under “Capital Resources and Liquidity.” Within the tables presented, percentages are calculated based on the underlying whole-dollar amounts and, therefore, may not recalculate exactly from the rounded numbers used for disclosure purposes.    

Non-GAAP Financial Measures

The succeeding sections of Management’s Discussion and Analysis (MD&A) may include certain financial measures that are not defined by accounting principles generally accepted in the United States (GAAP). These measures, which are referred to as non-GAAP measures, are listed below:
Free Cash Flow - Free cash flow is calculated as net cash provided by operating activities less capital expenditures.
Constant currency - Constant currency is defined as excluding the effect of foreign currency fluctuations.
For a discussion of these measures and the reasons management believes they are useful to investors, refer to “Summary of Non-GAAP Financial Measures” below. To the extent applicable, this MD&A includes reconciliations of these non-GAAP measures to the most directly comparable financial measures calculated and presented in accordance with GAAP.

The presentation of these non-GAAP financial measures is not intended to be a substitute for, or superior to, the financial information prepared and presented in accordance with GAAP and may be different from non-GAAP financial measures used by other companies, and therefore, may not be comparable among companies.

COVID-19 Considerations

The World Health Organization categorized the Coronavirus disease 2019 (COVID-19) as a pandemic. The COVID-19 pandemic has caused a severe global health crisis, along with economic and societal disruptions and uncertainties, which have negatively impacted business and healthcare activity globally. As a result of healthcare systems responding to the demands of managing the pandemic, governments around the world imposing measures designed to reduce the transmission of the COVID-19 virus, and individuals responding to the concerns of contracting the COVID-19 virus, many optical practitioners and retailers, hospitals, medical offices and fertility clinics closed their facilities, restricted access, or delayed or canceled patient visits, exams and elective medical procedures, and many customers that have reopened are experiencing reduced patient visits. These factors have had, and in the future may have, an adverse effect on our sales, operating results and cash flows.

We have taken an active role in addressing the ongoing pandemic’s impact on our employees, suppliers, distribution channels, operations and customers, including taking precautionary measures, such as implementing contingency plans, and making operational adjustments as necessary. We have taken measures to help ensure the safety of our personnel in all our facilities, and we have endeavored and continue to follow recommended actions of government and health authorities to protect our employees worldwide.

As of the date of this filing, we have not experienced any significant disruption at our manufacturing facilities. We have had no significant disruption in our access to necessary raw materials and other supplies or with our distribution network; however, we have experienced higher unabsorbed fixed overhead costs, labor inefficiencies, higher cost of production and higher freight charges as a result of the COVID-19 pandemic. As a result, we instituted an inventory control project to reduce buildup of excess inventory. Our manufacturing and distribution operations have responded to the impacts related to the COVID-19 pandemic, and we have been able to continue to supply our products around the world without interruption. In the future, we may decide or need to implement additional precautionary measures or operational adjustments as we deem prudent to meet consumer demand or to help further ensure employee safety. We believe that the actions we are taking have enabled us to keep our employees safe and our supply chain intact and will help us emerge from this global pandemic operationally sound and well positioned for long-term growth.

The extent to which the global COVID-19 pandemic and related economic disruptions impact our business, results of operations, cash flow and financial condition will depend on future developments. At this time, future developments are highly uncertain, difficult to predict and largely outside of our control. These include, but are not limited to, the spread,
24


THE COOPER COMPANIES, INC. AND SUBSIDIARIES
Item 2. Management’s Discussion and Analysis of Financial Condition
and Results of Operations
duration and severity of the pandemic outbreak and any subsequent waves of additional outbreaks, actions taken by governments to contain the pandemic, address its impact or respond to the reduction in global and local economic activity, and how quickly and to what extent normal economic and operating conditions can resume. We will continue to closely monitor the developments relating to the COVID-19 pandemic and the responses from governments and private sector participants and their respective impact on our Company and on our customers, suppliers, vendors and business partners.

COO-20210430_G1.JPG

Second Quarter Highlights
Gross profit of $487.1 million, up 51% from $323.5 million in the prior year period
Operating income of $143.2 million, up 401% from $28.6 million in the prior year period
Diluted earnings per share of $2.36, up 922% from $0.23 per share in the prior year period
Cash provided by operations of $192.6 million, compared to $25.8 million in the prior year period

Six Months Highlights
Gross profit $937.8 million, up 25% from $750.0 million in the prior year period
Operating income $276.6 million, up 98% from $139.7 million in the prior year period
Diluted earnings per share of $44.65, up 2076% from $2.05 per share in the prior year period
Cash provided by operations $340.3 million, compared to $155.5 million in the prior year period.
Outlook
Overall, we remain optimistic about the long-term prospects for the worldwide contact lens and general health care markets. However, the impact, risks and uncertainty relating to the global COVID-19 pandemic and related economic disruptions, as further described in the “COVID-19 Considerations” section above and in the “Risk Factors” section in Part II, Item 1A of this filing, have adversely affected our sales, cash flow and current performance and are likely to further adversely affect our future sales, cash flow and performance. Additionally, other events affecting the economy as a whole, including but not limited to the uncertainty and instability of global markets driven by foreign currency volatility, changes in tax legislation, debt concerns, the uncertainty following the United Kingdom's withdrawal from the EU, changes to existing regulations and new regulations, global trade barriers including additional tariffs and the trend of consolidations within the health care industry could impact our current performance and continue to represent a risk to our future performance.
CooperVision - We compete in the worldwide contact lens market with our spherical, toric, multifocal, toric multifocal and myopia management contact lenses offered in a variety of materials including using silicone hydrogel Aquaform® technology, PC Technology™ and ActivControl® technology. We believe that there will be lower contact lens wearer dropout rates as technology improves and enhances the wearing experience through a combination of improved designs and
25


THE COOPER COMPANIES, INC. AND SUBSIDIARIES
Item 2. Management’s Discussion and Analysis of Financial Condition
and Results of Operations
materials and the growth of preferred modalities such as single-use and monthly wearing options. CooperVision also competes in the myopia management and specialty eye care markets with products such as ortho-k and scleral lenses. In November 2019, CooperVision received United States Food and Drug Administration (FDA) approval for its MiSight® 1 day lens, which is the first and only FDA-approved product indicated to slow the progression of myopia in children with treatment initiated between the ages of 8-12 and became available in the United States during fiscal 2020. CooperVision is focused on greater worldwide market penetration using recently introduced products, and we continue to expand our presence in existing and emerging markets, including through acquisitions.
CooperVision acquired the following entities during the six months ended April 30, 2021:
•    A privately-held U.K. contact lens manufacturer on April 26, 2021
•    A privately-held medical device company on January 19, 2021

Our ability to compete successfully with a full range of silicone hydrogel products is an important factor to achieving our desired future levels of sales growth and profitability. CooperVision manufactures and markets a wide variety of silicone hydrogel contact lenses. Our single-use silicone hydrogel product franchises, clariti® and MyDay®, remain a focus as we expect increasing demand for these products as well as future single-use products as the global contact lens market continues to shift to this modality. Outside of single-use, the Biofinity® and Avaira Vitality® product families comprise our focus in the FRP, or frequent replacement product, market which encompasses the 2-week and monthly modalities. Included in this segment are unique products such as Biofinity Energys®, which helps individuals with digital eye fatigue.
CooperSurgical - Our CooperSurgical business competes in the general health care market with a commitment to advancing the health of women, babies and families through its diversified portfolio of products and services focusing on women's health and fertility. CooperSurgical has established its market presence and distribution system by developing products and acquiring companies, products and services that complement its business model.
CooperSurgical acquired the following entities during the six months ended April 30, 2021:
•    A privately-held medical device company on March 1, 2021
•    A privately-held medical device company on February 1, 2021
•    A privately-held in vitro fertilization (IVF) cryo-storage software solutions company on December 31, 2020
CooperSurgical acquired the following entity during the six months ended April 30, 2020:
A privately-held distributor of IVF medical devices and systems on December 13, 2019

Capital Resources - At April 30, 2021, we had $105.9 million in unrestricted cash, primarily held outside the United States, and $813.6 million available under our 2020 Credit Agreement. The $850.0 million term loan entered into on April 1, 2020, and the $350.0 million term loan entered into on October 16, 2020, remain outstanding as of April 30, 2021.
See Note 5. Debt of the Consolidated Condensed Financial Statements for additional information.

Transition from LIBOR

The United Kingdom’s Financial Conduct Authority, which regulates the London Interbank Offered Rate (LIBOR), announced in July 2017 that it will no longer persuade or require banks to submit rates for LIBOR after 2021. Further, in March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting. This guidance provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The Company has material contracts that are indexed to LIBOR and is continuing to monitor this activity and evaluate the related risk. We are continuing to evaluate the scope of impacted contracts and the potential impact. We are also monitoring the developments regarding alternative rates and may amend certain contracts to accommodate those rates if the contract does not already specify a replacement rate. While the notional value of agreements potentially indexed to LIBOR is material, we are not yet able to reasonably estimate the expected impact.

26


THE COOPER COMPANIES, INC. AND SUBSIDIARIES
Item 2. Management’s Discussion and Analysis of Financial Condition
and Results of Operations
Selected Statistical Information – Percentage of Net Sales
Three Months Six Months
Percentage of Net Sales 2021 vs 2020 % Change in Absolute Values Percentage of Net Sales 2021 vs 2020 % Change in Absolute Values
Periods Ended April 30, 2021 2020 2021 2020
Net sales 100  % 100  % 37  % 100  % 100  % 20  %
Cost of sales 32  % 38  % 15  % 33  % 36  % 10  %
Gross profit 68  % 62  % 51  % 67  % 64  % 25  %
Selling, general and administrative expense 40  % 45  % 20  % 39  % 42  % 10  %
Research and development expense % % (12) % % % (8) %
Amortization of intangibles % % 10  % % % %
Operating income 20  % % 401  % 20  % 12  % 98  %
Net Sales Growth by Business Unit
Periods Ended April 30, Three Months Six Months
($ in millions) 2021 2020 Increase 2021 vs 2020 % Change 2021 2020 Increase 2021 vs 2020 % Change
CooperVision $ 522.6  $ 402.2  $ 120.4  30  % $ 1,029.6  $ 887.4  $ 142.2  16  %
CooperSurgical 196.9  122.7  74.2  60  % 370.4  283.7  86.7  31  %
Net sales $ 719.5  $ 524.9  $ 194.6  37  % $ 1,400.0  $ 1,171.1  $ 228.9  20  %
CooperVision Net Sales
The contact lens market has two major product categories:
Spherical lenses including lenses that correct near- and farsightedness uncomplicated by more complex visual defects; and
Toric and multifocal lenses including lenses that, in addition to correcting near- and farsightedness, address more complex visual defects such as astigmatism and presbyopia by adding optical properties of cylinder and axis, which correct for irregularities in the shape of the cornea.
CooperVision Net Sales by Category
COO-20210430_G2.JPG COO-20210430_G3.JPG
27


THE COOPER COMPANIES, INC. AND SUBSIDIARIES
Item 2. Management’s Discussion and Analysis of Financial Condition
and Results of Operations
Three Months Ended April 30, 2021 vs 2020
% Change
($ in millions) 2021 2020
Toric $ 172.8  $ 133.6  29  %
Multifocal 58.0  45.1  29  %
Single-use spheres 144.5  116.1  24  %
Non single-use sphere, other 147.3  107.4  37  %
$ 522.6  $ 402.2  30  %
COO-20210430_G4.JPG COO-20210430_G5.JPG
Six Months Ended April 30, 2021 vs 2020
% Change
($ in millions) 2021 2020
Toric $ 335.1  $ 288.7  16  %
Multifocal 115.7  96.9  19  %
Single-use spheres 290.5  254.2  14  %
Non single-use sphere, other 288.3  247.6  16  %
$ 1,029.6  $ 887.4  16  %
In the three and six months ended April 30, 2021:
Toric and multifocal lenses grew primarily through the success of Biofinity and MyDay.
Single-use sphere lenses growth was primarily attributed to MyDay and clariti lenses.
"Other" products primarily include lens care which represented approximately 2% of net sales in both the three and six months ended April 30, 2021 and 2020.
Total silicone hydrogel products increased by 36% and 21% in the three and six months ended April 30, 2021, representing 77% of net sales, compared to 73% in the three and six months ended April 30, 2020.
Foreign exchange rates positively impacted sales by approximately $21.5 million and $36.3 million in the three and six months ended April 30, 2021 and had a negative impact of $7.5 million and $9.7 million in the prior year periods. In the three and six months ended April 30, 2021, net sales increased by 25% and 12% in constant currency over the prior year periods.
28


THE COOPER COMPANIES, INC. AND SUBSIDIARIES
Item 2. Management’s Discussion and Analysis of Financial Condition
and Results of Operations
Sales growth was primarily driven by an increase in the volume of lenses sold across our core portfolio due to a recovery in demand from the impact of the COVID-19 pandemic. Average realized prices by product did not materially influence sales.
We expect to continue seeing downward pressure and volatility in certain markets related to net sales if the COVID-19 pandemic continues, as optical retailers and healthcare centers continue to restrict access, and social distancing measures continue.
CooperVision Net Sales by Geography

CooperVision competes in the worldwide soft contact lens market and services in three primary regions: the Americas, EMEA (Europe, Middle East and Africa) and Asia Pacific.
Periods Ended April 30, Three Months Six Months
($ in millions) 2021 2020 2021 vs 2020
% Change
2021 2020 2021 vs 2020
% Change
Americas $ 207.5  $ 149.6  39  % $ 407.9  $ 339.0  20  %
EMEA 194.2  154.1  26  % 383.0  341.1  12  %
Asia Pacific 120.9  98.5  23  % 238.7  207.3  15  %
$ 522.6  $ 402.2  30  % $ 1,029.6  $ 887.4  16  %

CooperVision's growth in net sales across all regions was primarily attributable to market gains of silicone hydrogel contact lenses and favorable foreign currency impacts. Refer to CooperVision Net Sales by Category above for further discussion.
CooperSurgical Net Sales by Category
CooperSurgical supplies the family health care market with a diversified portfolio of products and services. Our office and surgical offerings include products that facilitate surgical and non-surgical procedures that are commonly performed primarily by obstetricians and gynecologists in hospitals, surgical centers, fertility clinics and medical offices. Fertility offerings include highly specialized products and services that target the IVF process, including diagnostics testing with a goal to make fertility treatment safer, more efficient and convenient.
The chart below shows the percentage of net sales of office and surgical products and fertility.
COO-20210430_G6.JPG COO-20210430_G7.JPG
29


THE COOPER COMPANIES, INC. AND SUBSIDIARIES
Item 2. Management’s Discussion and Analysis of Financial Condition
and Results of Operations
Three Months Ended April 30, 2021 vs 2020
% Change
($ in millions) 2021 2020
Office and surgical products $ 112.6  $ 69.6  62  %
Fertility 84.3  53.1  58  %
$ 196.9  $ 122.7  60  %
COO-20210430_G8.JPG COO-20210430_G9.JPG
Six Months Ended April 30, 2021 vs 2020
% Change
($ in millions) 2021 2020
Office and surgical products $ 216.1  $ 168.0  29  %
Fertility 154.3  115.7  33  %
$ 370.4  $ 283.7  31  %

In the three and six months ended April 30, 2021:
Office and surgical products increased compared to the prior year periods mainly due to an increase in PARAGARD® sales compared to the prior year periods. Further, there was an increase from other office and surgical products such as Uterine Manipulators, Retractors, Closure products, LEEP products and Point-of-Care products.
Fertility net sales increased compared to the prior year periods mainly due to an increase in revenue from IVF consumables, equipment sales, preimplantation genetic testing and sales from our recent acquisition, Embryo Options.
Foreign exchange rates positively impacted sales by approximately $3.0 million and $4.1 million in the three and six months ended April 30, 2021 and had a negative impact of $1.4 million and $2.1 million in the prior year periods. In the three and six months ended April 30, 2021, net sales increased by 58% and 29% in constant currency over the prior year periods.
Sales growth was primarily driven by stronger demand for our products and services as a result of our customers continuing to reopen their health care facilities and medical offices.
We expect to continue seeing downward pressure and volatility in certain markets related to net sales if the COVID-19 pandemic continues, as hospitals and healthcare centers continue to restrict access, and social distancing measures continue.

30


THE COOPER COMPANIES, INC. AND SUBSIDIARIES
Item 2. Management’s Discussion and Analysis of Financial Condition
and Results of Operations
Gross Margin

Consolidated gross margins were 68% and 67% in the three and six months ended April 30, 2021, up from 62% and 64% in the prior year periods, primarily driven by product mix and favorable currency.

Selling, General and Administrative Expense (SGA)
Three Months Ended April 30, 2021 vs 2020
% Change
($ in millions) 2021 % Net Sales 2020 % Net Sales
CooperVision $ 194.5  37  % $ 160.8  40  % 21  %
CooperSurgical 79.7  40  % 62.9  51  % 27  %
Corporate 11.6  —  13.5  —  (14) %
$ 285.8  40  % $ 237.2  45  % 20  %
Six Months Ended April 30, 2021 vs 2020
% Change
($ in millions) 2021 % Net Sales 2020 % Net Sales
CooperVision $ 373.6  36  % $ 333.2  38  % 12  %
CooperSurgical 150.3  41  % 135.3  48  % 11  %
Corporate 23.1  —  27.0  —  (14) %
$ 547.0  39  % $ 495.5  42  % 10  %

CooperVision's SGA increased in the three and six months ended April 30, 2021 compared to fiscal 2020 primarily due to increases in distribution costs, general and administrative costs and advertising and marketing activities primarily related to myopia management, partially offset by lower travel expenses due to the COVID-19 pandemic. CooperVision's SGA in the three and six months ended April 30, 2021 included $1.1 million and $3.0 million of costs primarily related to acquisition and integration activities. CooperVision's SGA in the three and six months ended April 30, 2020 included $0.8 million and $1.4 million of costs primarily related to integration activities.
CooperSurgical's SGA increased in the three and six months ended April 30, 2021 compared to fiscal 2020 primarily due to increases in selling expenses, partially offset by lower advertising and marketing costs and travel expenses due to the COVID-19 pandemic. CooperSurgical's SGA in the three and six months ended April 30, 2021 included $4.9 million and $6.7 million of acquisition and integration expenses and legal settlement. CooperSurgical's SGA in the three and six months ended April 30, 2020 included $4.4 million and $10.5 million of integration expenses and European Medical Devices Regulation costs.
Corporate SGA decreased in the three and six months ended April 30, 2021 compared to fiscal 2020 primarily due to savings from lower travel expenses due to the COVID-19 pandemic and timing of corporate projects.
Research and Development Expense (R&D)
Three Months Ended April 30, 2021 vs 2020
% Change
($ in millions) 2021 % Net Sales 2020 % Net Sales
CooperVision 13.8  % 12.8  % %
CooperSurgical 7.2  % 11.0  % (35) %
21.0  % 23.8  % (12) %
Six Months Ended April 30, 2021 vs 2020
% Change
($ in millions) 2021 % Net Sales 2020 % Net Sales
CooperVision 27.9  % 25.9  % %
CooperSurgical 14.5  % 20.1  % (28) %
42.4  % 46.0  % (8) %
In the three and six months ended April 30, 2021:
31


THE COOPER COMPANIES, INC. AND SUBSIDIARIES
Item 2. Management’s Discussion and Analysis of Financial Condition
and Results of Operations
CooperVision's R&D expense increased in the three and six months ended April 30, 2021 compared to fiscal 2020, mainly due to MiSight and timing of R&D projects. As a percentage of sales, CooperVision's R&D expense remained relatively flat. CooperVision's R&D activities are primarily focused on the development of contact lenses, manufacturing technology and process enhancements.
CooperSurgical's R&D expense decreased in the three and six months ended April 30, 2021 compared to fiscal 2020, mainly due to timing of R&D projects and changes in headcount. CooperSurgical has not paused research programs during the COVID-19 pandemic and has maintained its spend on innovations and increased its spend on key regulatory investment areas to support our long-term objectives. As a percentage of sales, CooperSurgical's R&D expense decreased, primarily due to an increase in net sales. CooperSurgical's R&D activities are focused on upgrading existing and developing new products ranging from diagnostics, surgical devices to fertility instruments and solutions.
Amortization Expense